The future of primary intraocular lymphoma (retinal lymphoma).
Basic science and clinical investigations in cancer research have contributed to our understanding of the genetic causes of various neoplasms and discovery of novel therapeutic interventions to fight malignancies such as lymphoma. During this exciting time, we have witnessed the advent of new technologies to further characterize primary intraocular lymphoma (PIOL), or retinal lymphoma, which is selected as the first "Disease of the Year" by Ocular Immunology and Inflammation. Different comprehensive aspects of PIOL, including epidemiology, clinical manifestations, diagnosis, pathophysiology, therapy, and animal models are discussed. The future of PIOL holds an opportunity to really understand the unique cytologic, histopathologic, physiological and immunologic features, as well as the genotypic traits (gene expression, interaction, polymorphism, epigenetics, etc.) and epidemiology. This information will empower us to truly make a difference in patients' managements with this devastating disease. While most of this technology already exists, much work still needs to be done to make translational therapy a reality for PIOL patients in the future.
Chan
Chi-Chao
CC
Immunopathology Section, Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20895, USA. chanc@nei.nih.gov
Fisson
Sylvain
S
Bodaghi
Bahram
B
D000818:Animals; D004195:Disease Models, Animal; D044127:Epigenesis, Genetic; D006801:Humans; D007239:Infections / Q000150:complications; D008223:Lymphoma / Q000175:diagnosis / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy; D020411:Oligonucleotide Array Sequence Analysis; D020641:Polymorphism, Single Nucleotide; D019572:Retinal Neoplasms / Q000175:diagnosis / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy